Regeneron Pharmaceuticals Inc (REGN) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $770.79
• Market Cap: $82.91B
• P/E Ratio: 18.90
• EPS: $41.49
• 52-Week High: $820.12
• 52-Week Low: $474.60

Market Sentiment

Regeneron Pharmaceuticals Inc currently has a Bullish sentiment score of 0.27.

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a prominent American biotechnology firm headquartered in Westchester County, New York, renowned for its pioneering research and development in monoclonal antibodies and therapeutic proteins. With a diverse portfolio that spans critical therapeutic areas such as oncology, ophthalmology, and immunology, Regeneron is celebrated for its flagship products, including Eylea and Dupixent. The company boasts a strong and innovative pipeline, reflecting its unwavering...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Regeneron Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does REGN pay dividends?

Regeneron Pharmaceuticals Inc (REGN) does not currently pay a regular dividend.

What is REGN's P/E ratio?

Regeneron Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 18.90.

What is REGN's market cap?

Regeneron Pharmaceuticals Inc (REGN) has a market capitalization of $82.91B with a current stock price of $770.79.